704 m doses of COVID-19 vaccine have been administered in 193 countries, areas, territories & economies

27 countries have not yet started vaccination

1. Source: Bloomberg. 76% in top 10 countries (largely high income and/or vaccine-producing countries)
Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Of WHO’s 194 Member States, 167 have started COVID-19 vaccination at least 8 additional MS received vaccine & can start in the coming days.

WHO Member States
N= 194

- AFRO N= 47
  - Started: 36 (79.1%)
  - Not started: 11 (20.9%)

- AMRO N= 35
  - Started: 33 (94.3%)
  - Not started: 2 (5.7%)

- EMRO N= 21
  - Started: 18 (85.7%)
  - Not started: 3 (14.3%)

- EURO N= 53
  - Started: 52 (98.1%)
  - Not started: 1 (1.9%)

- SEARO N= 11
  - Started: 9 (81.8%)
  - Not started: 2 (18.2%)

- WPRO N= 27
  - Started: 19 (70.4%)
  - Not started: 8 (29.6%)

1 Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Comoros, Democratic Republic of Congo, Eritrea, Madagascar, United Republic of Tanzania, Zambia
2 Cuba, Haiti
3 Libya, Syrian Arab Republic, Yemen
4 Turkmenistan
5 Democratic People's Republic of Korea, Timor-Leste
6 Kiribati, Nauru, Samoa, Tonga, Tuvalu, Vanuatu, Cook Islands, Niue

Status of COVID-19 vaccine roll out
- Green: Started
- Red: Not started

Source: WHO COVID-19 dashboard, COVAX, Our World in Data
Additional key numbers on Covid-19 vaccine roll-out

- **121 days** since 1st country started vaccinating

- **95% of HIC/UMICs & 77% of LMIC/LICs** have started

- **77% of doses** administered in 10 countries

- At least **10 different vaccines** are in use¹ (4 platforms²)

- 4 of the vaccines have **WHO Emergency Use Listing**

---

1. Pfizer, Moderna, Gamaleya, Sinovac, Sinopharm, SII, Bharat Biotech, AZ, Johnson & Johnson, EpiVacCorona
2. Inactivated virus, mRNA, viral vector, peptide

Source: WHO COVID-19 dashboard, COVAX, Our World in Data
Of the 10 COVID-19 vaccines now in use, AstraZeneca & Pfizer products are the most prevalent

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Number of countries &amp; economies using the vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca - AZD1222 / SII - Covishield</td>
<td><img src="image" alt="Bar chart" /> 51 SII - Covishield only 5 AstraZeneca - AZD1222 only 122</td>
</tr>
<tr>
<td>Pfizer BioNTech - Comirnaty</td>
<td><img src="image" alt="Bar chart" /> 98</td>
</tr>
<tr>
<td>Moderna - mRNA-1273</td>
<td><img src="image" alt="Bar chart" /> 47</td>
</tr>
<tr>
<td>Beijing / Wuhan CNBG - Inactivated (Sinopharm)</td>
<td><img src="image" alt="Bar chart" /> 36</td>
</tr>
<tr>
<td>Gamaleya - Sputnik V</td>
<td><img src="image" alt="Bar chart" /> 33</td>
</tr>
<tr>
<td>Sinovac - CoronaVac</td>
<td><img src="image" alt="Bar chart" /> 17</td>
</tr>
<tr>
<td>Janssen - Ad26.COV 2.5</td>
<td><img src="image" alt="Bar chart" /> 6</td>
</tr>
<tr>
<td>Bharat - Covaxin</td>
<td><img src="image" alt="Bar chart" /> 3</td>
</tr>
<tr>
<td>SRCVB - EpiVacCorona</td>
<td><img src="image" alt="Bar chart" /> 1</td>
</tr>
</tbody>
</table>

86 economies are using 1 vaccine; 107 are using 2 or more vaccines

1. World Bank classification (2021) of 218 economies. Note: The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics.

Source: Our World in data, WHO, Government websites; Press research
There is a striking differential in the doses, administered by income level

Number of COVID-19 vaccine doses administered per 100 people

Source: WHO COVID-19 dashboard, World Bank
COVAX has now shipped >38M doses to 102 participants
incl. 50 LMIC/LICs; 24 participants started their first campaigns thanks to COVAX doses

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

*Kosovo: All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

SOURCE: COVAX, WHO COVID-19 dashboard, Our World in Data; Government websites; Press research
Of the 19 COVAX participants that have not yet started yet; 8 to 14 should be ready to start soon.

Status of the COVAX participants that have not started vaccinating

Number of participants:

- Doses received but vaccination not yet started: 5
- Doses ready for shipment: 3
- PO placed but doses not ready to be shipped: 4
- PO on hold: 2
- PO not yet placed as missing 1 or more requirement: 5
- COVAX participants: 19
- AMC-eligible but no confirmed participation in COVAX: 4
- COVAX participants and eligible economies: 23

These participants should be able to start vaccinating in the coming days / weeks.
Upcoming shipments (UNICEF Market Dashboard)

<table>
<thead>
<tr>
<th>Countries and territories, doses shipped</th>
<th>Doses allocated, through May</th>
<th>Doses Ordered, cumulative</th>
<th>Doses released for shipment, cumulative</th>
<th>Doses on shipment in transit</th>
<th>Doses Shipped, cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>98</td>
<td>201.63M</td>
<td>119.38M</td>
<td>40.65M</td>
<td>57,600</td>
<td>38,010,940</td>
</tr>
</tbody>
</table>

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

SOURCE: UNICEF Market dashboard
COVAX has faced a marked reduction in March & April supplies

Original Feb-May allocations

- **SII**: 237 M doses (142 participants)
- **AZ/SK Bio**: 1.2 M doses (18 participants)
- **Pfizer**: 1.2 M doses (18 participants)

Original plan for Feb-March

- **SII**: 70 M doses (60 participants)
- **AZ/SK Bio**: 25 M doses (82 participants)
- **Pfizer**: 1.2 M doses (18 participants)

Supplier problems

- **SII**: Mar/Apr doses not yet released (90m)
- **AZ/SK Bio**: 50% reduced March deliveries (12m)
- **Pfizer**: Pfizer shipping & liability requirements

Current status (24 March)

- **SII**: 28.2 M doses (39 participants)
- **AZ/SK Bio**: 9.0 M doses (61 participants)
- **Pfizer**: 0.8 M doses (13 participants)

Remaining doses contracted to deliver by end-May

- **SII**: 131 M doses?
- **AZ/SK Bio**: 67 M doses(?)
- **Pfizer**: 0.4M doses

These supply issues are affecting ALL countries/deals (e.g. EC3, CAN, UK, etc).

1. Q2 allocation (i.e. April-June); Still TBD
2. Of which, 5 had additional SII allocation and 13 had an additional AZ allocation
3. AZ will deliver 25M doses to EU countries in Q1 2021 vs. 100M initially planned
COVAX is now in its 3rd allocation round

<table>
<thead>
<tr>
<th>Period</th>
<th>Round #1</th>
<th>Round #2</th>
<th>Round #3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Announced</td>
<td>3 February</td>
<td>2 March</td>
<td>9 April (TBC)</td>
</tr>
<tr>
<td>Vaccine &amp; Number of doses</td>
<td>Pfizer 1.2M doses</td>
<td>SII &amp; AZ/SK Bio 237M doses</td>
<td>Pfizer 14M doses</td>
</tr>
<tr>
<td>Number of participants</td>
<td>18 participants</td>
<td>142 participants: 60 SII; 82 AZ/SK Bio</td>
<td>47 participants</td>
</tr>
</tbody>
</table>

Source: COVAX
### 6 urgent & ongoing initiatives to accelerate roll-out of COVAX Facility vaccines

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Establish with Govt of India COVAX supply of SII products for April-May</td>
</tr>
<tr>
<td>2</td>
<td>Accelerate release &amp; rollout of AZ/SKBio vaccines (batch release, label, etc)</td>
</tr>
<tr>
<td>3</td>
<td>Expedite delivery of newly EUL’d products through COVAX (e.g. J&amp;J)</td>
</tr>
<tr>
<td>4</td>
<td>Pursue donations of vaccines that have WHO Emergency Use Listing</td>
</tr>
<tr>
<td>5</td>
<td>Expedite review of additional products (e.g. Sinopharm, Sinovac, Gamaleya)</td>
</tr>
<tr>
<td>6</td>
<td>Expand global manufacturing capacity of COVID-19 vaccines</td>
</tr>
</tbody>
</table>
4 months after the first dose administered in a high-income economy, 193 economies have started vaccinating

Status of Covid-19 vaccination campaigns in economies classified by income level, Number of economies

- 89% of economies have started vaccinating as of 7 April 2021
- 25 economies have not started vaccinating yet
- 18 out of these 25 countries are low- or middle-income economies

Key take-aways

1. World Bank classification (2021)

Source: WHO COVID-19 dashboard, COVAX, Our World in Data
19 COVAX participants (out of 185) have not started vaccinating yet

Status of vaccination campaigns, Number of COVAX participants

- **Vaccination has not started**: 19 (10%)
- **Vaccination has started**: 166 (90%)

Key take-aways

- **19 out of 185 COVAX participants have not started vaccinating yet**
- **14 of these participants are LMICs/LICs**

---

1. Does not include 5 AMC-eligible economies without confirmed participation status (Burundi, Eritrea, Madagascar, Marshall Islands, Tanzania)

Source: WHO COVID-19 dashboard, COVAX, Our World in Data